These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1008 related items for PubMed ID: 21601352

  • 1. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ.
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
    van Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A, Bangma CH, Schröder FH.
    Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.
    van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, de Koning HJ, van der Kwast TH, Schröder FH.
    J Urol; 2005 Jul; 174(1):121-5. PubMed ID: 15947595
    [Abstract] [Full Text] [Related]

  • 8. Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.
    van Leeuwen PJ, Otto SJ, Kranse R, Roobol MJ, Bul M, Zhu X, de Koning H, Schröder FH.
    BJU Int; 2012 Jul; 110(2):188-94. PubMed ID: 22288823
    [Abstract] [Full Text] [Related]

  • 9. Prostate cancer mortality in the Finnish randomized screening trial.
    Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A.
    J Natl Cancer Inst; 2013 May 15; 105(10):719-25. PubMed ID: 23479454
    [Abstract] [Full Text] [Related]

  • 10. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
    Loeb S, Zhu X, Schroder FH, Roobol MJ.
    BJU Int; 2012 Dec 15; 110(11):1678-83. PubMed ID: 22998182
    [Abstract] [Full Text] [Related]

  • 11. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ, Grenabo A, Schröder FH, Hugosson J.
    J Natl Cancer Inst; 2007 Sep 05; 99(17):1296-303. PubMed ID: 17728218
    [Abstract] [Full Text] [Related]

  • 12. Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies.
    Schröder FH, van den Bergh RC, Wolters T, van Leeuwen PJ, Bangma CH, van der Kwast TH, Roobol MJ.
    Eur Urol; 2010 Feb 05; 57(2):256-66. PubMed ID: 19913350
    [Abstract] [Full Text] [Related]

  • 13. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
    Bokhorst LP, Zhu X, Bul M, Bangma CH, Schröder FH, Roobol MJ.
    BJU Int; 2012 Dec 05; 110(11):1654-60. PubMed ID: 23043563
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Roemeling S, Roobol MJ, Gosselaar C, Schröder FH.
    Prostate; 2006 Jul 01; 66(10):1076-81. PubMed ID: 16637077
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, Iborra F, Salama G, Rischmann P, Villers A.
    Prog Urol; 2009 Jul 01; 19(7):487-98. PubMed ID: 19559380
    [Abstract] [Full Text] [Related]

  • 19. Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam.
    de Vries SH, Postma R, Raaijmakers R, Roemeling S, Otto S, de Koning HJ, Schröder FH.
    Eur Urol; 2007 Feb 01; 51(2):366-74; discussion 374. PubMed ID: 16930812
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.